Stolz L - Search Results

1

Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms.

Erbe DV, Wang S, Zhang YL, Harding K, Kung L, Tam M, Stolz L, Xing Y, Furey S, Qadri A, Klaman LD, Tobin JF. Erbe DV, et al. Among authors: stolz l. Mol Pharmacol. 2005 Jan;67(1):69-77. doi: 10.1124/mol.104.005553. Epub 2004 Oct 8. Mol Pharmacol. 2005. PMID: 15475571

2

Administration of myostatin does not alter fat mass in adult mice.

Stolz LE, Li D, Qadri A, Jalenak M, Klaman LD, Tobin JF. Stolz LE, et al. Diabetes Obes Metab. 2008 Feb;10(2):135-42. doi: 10.1111/j.1463-1326.2006.00672.x. Diabetes Obes Metab. 2008. PMID: 18190427

3

Myostatin mutation associated with gross muscle hypertrophy in a child.

Schuelke M, Wagner KR, Stolz LE, Hübner C, Riebel T, Kömen W, Braun T, Tobin JF, Lee SJ. Schuelke M, et al. N Engl J Med. 2004 Jun 24;350(26):2682-8. doi: 10.1056/NEJMoa040933. N Engl J Med. 2004. PMID: 15215484 Free article. No abstract available.

4

Ecallantide: a plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema.

Stolz LE, Horn PT. Stolz LE, et al. Drugs Today (Barc). 2010 Aug;46(8):547-55. doi: 10.1358/dot.2010.46.8.1507205. Drugs Today (Barc). 2010. PMID: 20830315 Review.

5

In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates.

Musunuru K, Chadwick AC, Mizoguchi T, Garcia SP, DeNizio JE, Reiss CW, Wang K, Iyer S, Dutta C, Clendaniel V, Amaonye M, Beach A, Berth K, Biswas S, Braun MC, Chen HM, Colace TV, Ganey JD, Gangopadhyay SA, Garrity R, Kasiewicz LN, Lavoie J, Madsen JA, Matsumoto Y, Mazzola AM, Nasrullah YS, Nneji J, Ren H, Sanjeev A, Shay M, Stahley MR, Fan SHY, Tam YK, Gaudelli NM, Ciaramella G, Stolz LE, Malyala P, Cheng CJ, Rajeev KG, Rohde E, Bellinger AM, Kathiresan S. Musunuru K, et al. Nature. 2021 May;593(7859):429-434. doi: 10.1038/s41586-021-03534-y. Epub 2021 May 19. Nature. 2021. PMID: 34012082

6

Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema.

Stolz LE, Sheffer AL. Stolz LE, et al. Expert Rev Clin Immunol. 2012 Jan;8(1):25-32. doi: 10.1586/eci.11.81. Expert Rev Clin Immunol. 2012. PMID: 22149337 Clinical Trial.

7

Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks.

Craig TJ, Li HH, Riedl M, Bernstein JA, Lumry WR, MacGinnitie AJ, Stolz LE, Biedenkapp J, Chyung Y. Craig TJ, et al. J Allergy Clin Immunol Pract. 2015 Mar-Apr;3(2):206-212.e4. doi: 10.1016/j.jaip.2014.09.001. Epub 2014 Oct 29. J Allergy Clin Immunol Pract. 2015. PMID: 25609335 Free article.

8

Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks.

Sheffer AL, MacGinnitie AJ, Campion M, Stolz LE, Pullman WE. Sheffer AL, et al. Among authors: stolz le. Ann Allergy Asthma Immunol. 2013 Mar;110(3):184-188.e2. doi: 10.1016/j.anai.2012.12.007. Epub 2013 Jan 5. Ann Allergy Asthma Immunol. 2013. PMID: 23548529 Clinical Trial.

9

Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics.

MacGinnitie AJ, Campion M, Stolz LE, Pullman WE. MacGinnitie AJ, et al. Allergy Asthma Proc. 2012 Mar-Apr;33(2):178-85. doi: 10.2500/aap.2012.33.3528. Allergy Asthma Proc. 2012. PMID: 22525395

10

A phase 1 study investigating DX-2930 in healthy subjects.

Chyung Y, Vince B, Iarrobino R, Sexton D, Kenniston J, Faucette R, TenHoor C, Stolz LE, Stevens C, Biedenkapp J, Adelman B. Chyung Y, et al. Ann Allergy Asthma Immunol. 2014 Oct;113(4):460-6.e2. doi: 10.1016/j.anai.2014.05.028. Epub 2014 Jun 26. Ann Allergy Asthma Immunol. 2014. PMID: 24980392 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

183 results

Search Page

Filters